Avis Budget Group, Inc.

BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, today announced details of its next-generation in vivo CAR-T platform. The company plans to advance TPST-4003, its lead in vivo CAR-T product candidate, into a first investigator-initiated clinical trial in patients with nervous system autoimmune diseases, initially focusing on myasthenia gravis (“MG”) and multiple sclerosis (“MS”). The study is expected to enroll approximately 10 patients, with first patient dosing anticipated in the fourth quarter of 2026.

globenewswire.com - 2026-07-15 07:00:00

PARSIPPANY, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2026 financial results after the market close on Tuesday, July 28, 2026, and to host a conference call for institutional investors to discuss these results on Wednesday, July 29, 2026, at 8:30 a.m.

globenewswire.com - 2026-07-13 17:32:00

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,

gurufocus.com - 2026-07-13 09:00:00

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company's off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congrès de Montréal in Montréal, Canada on July 8 - 11, 2026.

globenewswire.com - 2026-07-06 08:30:00

Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer.

prnewswire.com - 2026-07-06 08:30:00

Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a rolling BLA submission for SPS, with pivotal single-arm Phase 2 data showing strong efficacy and safety, targeting FDA approval by late 2026. KYTX maintains a cash runway through 2028, supported by $236M in cash and a $150M credit facility, enabling completion of key trials and commercial launch preparation.

seekingalpha.com - 2026-07-06 07:15:59

Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering.

seekingalpha.com - 2026-07-04 10:10:17

CAR gains from rising demand for short-term vehicle rentals, but geopolitical risks, low liquidity and lack of dividend cloud its long-term outlook.

zacks.com - 2026-07-03 10:36:06

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.

benzinga.com - 2026-06-29 10:35:25

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Ovarian cancer CAR-T therapy, lira-cel, presentation highlights positive survival observations from ongoing Phase 1 clinical trial Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions, including Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., June 26, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium this week.

prnewswire.com - 2026-06-26 09:10:00

Pentwater Capital agrees to pay Avis Budget after it was accused of fueling excess volatility in the car-rental company's stock.

wsj.com - 2026-06-23 08:37:00

CAR shares jump 28% in a month as pricing improves, fleet utilization hits a 15-year high and earnings are projected to surge in 2026.

zacks.com - 2026-06-15 12:41:10

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1–2, and none required glucocorticoids for CRS management Additional translational data showed rapid vector clearance, polyclonal vector integration, and no evidence of non-specific transduction Proof-of-concept progress demonstrates leadership in next-generation cell therapies, with results presented in a late-breaking session at EHA 2026 BRIDGEWATER, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

globenewswire.com - 2026-06-15 08:00:00

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

globenewswire.com - 2026-06-14 03:15:00

Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily discounting its pipeline despite advanced pivotal trials and strong early efficacy signals. Ronde-cel's dual CD19/CD20 targeting and CD62L+ enrichment underpin durable responses, low severe toxicity, and potential for outpatient administration.

seekingalpha.com - 2026-06-13 12:23:38

Short sellers are piling into a wide-ranging group of names, with the latest Benzinga Pro data showing elevated bearish positioning across 10 stocks with short interest ranging from 37% to 87%.

benzinga.com - 2026-06-11 18:17:34

WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene's LNP platform in patients with MG; Clinical data expected in 1H 2027 FREDERICK, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced a strategic licensing agreement with WestGene Biopharma Co., Ltd.

globenewswire.com - 2026-06-09 07:00:00

Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.

marketbeat.com - 2026-06-09 06:06:02

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion  Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancers Investigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center") FRAMINGHAM, MA / ACCESS Newswire / June 4, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical study of a combination systemic DNase I with anti-CD19 CAR T Cells in large B cell lymphoma (LBCL) patients.

accessnewswire.com - 2026-06-04 08:40:00

BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (EHA) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.

globenewswire.com - 2026-06-02 09:30:00

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers Data to be presented today as a poster presentation at the ASCO 2026 annual meeting FRAMINGHAM, MA / ACCESS Newswire / June 1, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced positive preclinical data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. Presentation Details: Session Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster Session) Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR-T cell function and antitumor efficacy Poster Board: 410 Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT Presenter: Alexey V.

accessnewswire.com - 2026-06-01 09:02:00

Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radioconjugates, presenting tunable levers Actinium is utilizing to engineer more effective drug candidates Optimized CAR improved tumor targeting, internalization, and pharmacokinetics of 225Ac-labeled antibodies Lower-CAR conjugates preserved tumor targeting while reducing off-target liver and spleen uptake, supporting a wider therapeutic window that may enable higher, safer dosing Findings reinforce Actinium's proprietary radiochemistry expertise and directly support the Company's broader radioconjugate pipeline a capability that applies to every program from the platform NEW YORK, June 1, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on May 31, 2026 presented new radiochemistry data at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting taking place in Los Angeles, California. The poster presented a systematic evaluation of chelator-to-antibody ratio (CAR) optimization for Actinium-225 (225Ac)-labeled antibody radioconjugates, a critical but often underappreciated design parameter that directly influences radiolabeling efficiency, antigen binding, internalization, and biodistribution.

prnewswire.com - 2026-06-01 07:00:00

Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-05-29 12:31:31

On May 28, 2026, Avis Budget Group Inc (CAR) shares rose by 5.9%, bringing the current price to $174.88. This latest movement comes amid a 52-week range that ha

gurufocus.com - 2026-05-28 18:58:00

Avis Budget is expanding mobility partnerships and premium services as it positions itself beyond traditional car rentals.

zacks.com - 2026-05-28 14:55:35

PARSIPPANY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), priced a private offering of $300 million aggregate principal amount of additional 8.000% Senior Notes due 2031 (the “Notes”) in a private offering. The Notes will be issued as additional notes under the Indenture, dated as of November 22, 2023, pursuant to which the Issuers previously issued $500 million aggregate principal amount of 8.000% Senior Notes due 2031. The Notes will have a maturity date of February 15, 2031. The closing of the offering of the Notes is expected to occur on May 29, 2026, subject to customary closing conditions. The Notes were priced at 100.500% of its face value and will be guaranteed on a senior unsecured basis by the Company and certain of its U.S. subsidiaries.

globenewswire.com - 2026-05-27 17:21:00

TTEC's AI-driven turnaround, improving free cash flow and a stronger liquidity position it ahead of CAR's volatile recovery efforts.

zacks.com - 2026-05-27 12:50:42

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today announced that it has exercised its option to regain full ex vivo rights to HCW9206 and HCW9201, two commercial-ready compounds as reagents, from its licensee, Wugen Inc. Wugen held exclusive worldwide rights to these two compounds for ex vivo, cell-based therapy applications.

globenewswire.com - 2026-05-27 07:45:00

PARSIPPANY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), intend, subject to market and other customary conditions, to offer $300 million aggregate principal amount of additional 8.000% Senior Notes due 2031 (the “Notes”) in a private offering.

globenewswire.com - 2026-05-27 07:30:00

Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel.

marketbeat.com - 2026-05-27 04:03:24

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026.

globenewswire.com - 2026-05-21 08:30:00

HANGZHOU, China--(BUSINESS WIRE)--Qihan Biotech, a biotechnology company dedicated to applying high-throughput, multiplexed gene editing technologies to cell therapy and organ transplantation, announced today that QT-019C has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). QT-019C is a universal allogeneic CAR-T cell therapy independently developed by Qihan Biotech using the company's proprietary intellectual property. A distinguishing innovat.

businesswire.com - 2026-05-20 09:00:00

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced upcoming data presentations at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3 – 6, 2026 in London. The five accepted abstracts will be delivered as one late-breaking oral presentation, one oral presentation, one poster view, one poster tour and one publication only.

globenewswire.com - 2026-05-19 16:05:00

CAR's pricing rebound and tighter fleet management are boosting utilization and improving depreciation trends.

zacks.com - 2026-05-19 10:25:23

CAR's pricing recovery and Waymo partnership offer long-term potential, but April's 70% stock collapse exposed major volatility risks.

zacks.com - 2026-05-18 13:20:49

Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress. Key catalysts include registrational trials for rese-cel in myositis, promising early data in myasthenia gravis and pemphigus vulgaris, and upcoming SLE and SSc readouts. Rese-cel's outpatient-friendly safety profile, removal of preconditioning, and scalable manufacturing platform position CABA for significant autoimmune market opportunities.

seekingalpha.com - 2026-05-14 10:46:41

SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in non-human primates (NHPs) without the use of lymphodepleting chemotherapy. SG293 is a CD8-targeted fusosome that delivers the genetic material to make CD19-directed CAR T cells.

globenewswire.com - 2026-05-12 16:05:00

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models  Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models.

globenewswire.com - 2026-05-12 08:00:00

Multiple patients have survived substantially beyond expected median survival, including onepatient who survived 28 months and several patients who remain alive with continued follow-up Lira-cel clinical trial featured in presentation at the International Society for Cell & Gene Therapy2026 Annual Meeting SAN JOSE, Calif., May 11, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the Company's follicle-stimulating hormone receptor ("FSHR")-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.

prnewswire.com - 2026-05-11 08:55:00

Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust ("CAPREIT") (TSX: CAR.UN) announced today its operating and financial results for the three months ended March 31, 2026.

globenewswire.com - 2026-05-07 17:00:00

Avis Budget's Q1 loss misses estimates as fleet charges stay high, but revenues beat and utilization hit a first-quarter record in more than 15 years.

zacks.com - 2026-05-06 11:26:23

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs FT819, FT839, and FT836, will be featured at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held in Boston, MA, May 11–15, 2026. Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to background maintenance therapy without the use of conditioning chemotherapy to drive B cell depletion and improve patient outcome.

globenewswire.com - 2026-05-04 09:00:00

Bristol Myers Squibb faces a major patent cliff but is well-equipped with a robust pipeline and significant CAR-T optionality. BMY trades at a discounted 9.4x forward P/E, reflecting patent cliff fears, yet offers 15-20% base case upside plus a 4.3% dividend yield. The 2026 catalyst stack includes Milvexian, Iberdomide, Cobenfy, and Sotyktu, any of which could drive a rerating to 10x-11x forward P/E.

seekingalpha.com - 2026-05-02 03:20:18

Pre-Market Stock Futures: Futures are trading mixed as we get ready to finish off another wild week. What a difference a day makes: after a flat-to-down Wednesday, all the major indices exploded higher on Thursday and closed solidly in the green. Big earnings for members of the Magnificent 7, oil prices falling somewhat, and while... Here Are Friday's Top Wall Street Analyst Research Calls: Avis Budget, Caterpillar, Celestica, Commvault Systems, Ciena, Dutch Bros. e.l.f. Beauty, Hershey, Roblox, and More

247wallst.com - 2026-05-01 07:59:20

Shares of Hertz (NASDAQ:HTZ) are up 13% on Thursday at roughly $6.35, while Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) stock is only up 2% to around $184.50.

247wallst.com - 2026-04-30 14:05:46

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that clinical data from the Company's off-the-shelf CAR T-cell product candidate, FT819, will be featured at the Congress of Clinical Rheumatology – East meeting, being held in Destin, FL on April 30 - May 3, 2026. The Company is participating in a Poster Rounding Session and will present an encore of its clinical data from the systemic lupus erythematosus (SLE) study arm of its ongoing Phase 1 trial evaluating FT819 in various autoimmune diseases.

globenewswire.com - 2026-04-30 09:00:00

The rental car company says a hedge-fund firm behind the big swings owes it money because of a niche trading rule.

wsj.com - 2026-04-29 17:49:00

Avis Budget Group, Inc. (CAR) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-29 11:41:44

Although the revenue and EPS for Avis Budget (CAR) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-04-29 11:31:08

Avis Budget Group, Inc. (NASDAQ:CAR) shares are trading lower Wednesday after the company reported mixed first-quarter results.

benzinga.com - 2026-04-29 10:03:27